This article explores the current state of artificial intelligence (AI) in drug discovery and development,
discussing the obstacles holding back wider adoption. Dr Mark Eller, Senior Vice President of Research
and Development at Aria Pharmaceuticals, makes the case that to succeed, AI must be integrated as a
partner alongside core pharmaceutical R&D disciplines.